Literature DB >> 22863396

Thyroid dermopathy and acropachy.

Vahab Fatourechi1.   

Abstract

Graves' disease is an autoimmune condition commonly associated with thyroid dysfunction and with anti-thyroid antibodies, usually TSH receptor stimulating antibodies. Thyroid autoimmunity also may be associated with extra thyroidal manifestations. Most common extra thyroidal manifestation is ophthalmopathy. Less common is thyroid dermopathy, usually occurring in pretibial area. Dermopathy is almost always associated with ophthalmopathy and in severe cases with acropachy. A common antigen with thyroid in tissues of the skin and the eyes, most likely TSH receptor, is involved in pathogenesis of extra thyroidal manifestations. Presence of dermopathy and acropachy are predictors of severity of autoimmune process. Local corticosteroid application is the standard therapy for dermopathy. Response to therapy is good in mild cases and poor in severe cases. Immune modulators and biotherapies are undergoing randomized trials for ophthalmopathy component of Graves' disease. Any therapy proven to be effective for ophthalmopathy can be utilized in future for management of dermopathy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22863396     DOI: 10.1016/j.beem.2011.10.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  14 in total

Review 1.  Diagnosis and management of Graves disease: a global overview.

Authors:  Luigi Bartalena
Journal:  Nat Rev Endocrinol       Date:  2013-10-15       Impact factor: 43.330

2.  Elephantiasic Pretibial Myxedema with Graves' Disease: Spontaneously Induced and Dramatically Resolved after Radioiodine Treatment.

Authors:  Jun Yang; Meng-Jie Dong; Qin Xu
Journal:  Eur Thyroid J       Date:  2019-11-14

Review 3.  Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review.

Authors:  Xueting Li; Senmao Li; Wanlin Fan; Alexander C Rokohl; Sitong Ju; Xiaojun Ju; Yongwei Guo; Ludwig M Heindl
Journal:  Int Ophthalmol       Date:  2022-10-22       Impact factor: 2.029

Review 4.  Hyperthyroidism.

Authors:  Simone De Leo; Sun Y Lee; Lewis E Braverman
Journal:  Lancet       Date:  2016-03-30       Impact factor: 79.321

Review 5.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

6.  Treatment of pretibial myxedema with intralesional immunomodulating therapy.

Authors:  Ziwei Ren; Min He; Fang Deng; Yan Chen; Liyin Chai; Bing Chen; Wuquan Deng
Journal:  Ther Clin Risk Manag       Date:  2017-09-08       Impact factor: 2.423

7.  Utility of rituximab treatment for exophthalmos, myxedema, and osteoarthropathy syndrome resistant to corticosteroids due to Graves' disease: a case report.

Authors:  Aldo Ferreira-Hermosillo; Ruben Casados-V; Pedro Paúl-Gaytán; Victoria Mendoza-Zubieta
Journal:  J Med Case Rep       Date:  2018-02-16

8.  Thyroid acropachy: A rare skeletal manifestation of autoimmune thyroid disease.

Authors:  Jami Jadidi; Maziar Sigari; Aslan Efendizade; Arkadij Grigorian; Scott A Lehto; Srinivas Kolla
Journal:  Radiol Case Rep       Date:  2019-05-23

9.  An atypical presentation of pretibial myxedema in a euthyroid patient with absent antithyroid autoantibodies.

Authors:  Derek Beaulieu; Kristin Nord
Journal:  JAAD Case Rep       Date:  2021-04-28

10.  Elephantiasic Graves' Dermopathy in a Patient with Negative Thyroid-Receptor Auto-Antibodies.

Authors:  Agnethe Berglund; Jette Lindorff Riis; Niels Henrik Vinther Krarup; Eva Spaun; Eva Ebbehøj
Journal:  Ann Dermatol       Date:  2017-12-26       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.